The Calmer Co (ASX: CCO) is emerging as an interesting small-cap growth story, with accelerating supermarket sales, a new consumer product launch and international distribution agreements potentially worth millions. As the company expands beyond traditional kava products into mainstream retail and global ingredients supply, investors are beginning to see a broader commercial opportunity taking shape.
The company is positioning itself to capitalise on growing interest in kava, a traditional Pacific Island botanical increasingly marketed through wellness products, functional beverages and alternatives to alcohol.
What has caught our attention is CCO's strategy of combining established supermarket distribution with product innovation and international wholesale opportunities. For a business generating $8.12 million in annual revenue, even modest improvements in consumer adoption could materially change its growth trajectory.
Coles and Woolworths sales are gaining momentum
The latest Australian retail figures suggest CCO's Fiji Kava brand is building traction.
During the September 2026 quarter, sales of established products increased 27% at Coles and 33% at Woolworths compared with the previous quarter, excluding contributions from the new FZZR range.
The company now distributes its 150g root powder through 837 Coles stores, while its 50g product is available across 788 Coles stores and 1,006 Woolworths stores.
Management also reported that Woolworths sales have increased every quarter since the national launch in June 2025, with September delivering its strongest monthly performance.
For investors, the opportunity is shifting from securing supermarket shelf space to generating higher sales from an already extensive national distribution network.
If consumer awareness and repeat purchasing continue improving, CCO could increase revenue without requiring a proportionate expansion in retail outlets.
FZZR could unlock a new consumer market
October marks another commercial milestone with the rollout of FZZR Piña Colada 10-packs across 583 Coles stores.
Unlike traditional kava powders, FZZR uses an effervescent format that can be dissolved in water, consumed directly or chewed.
The product targets convenience and accessibility, potentially introducing kava to consumers who might otherwise overlook conventional preparations.
The scale of the opportunity becomes clearer when considering supermarket volumes.
If each participating Coles store sold just five packs weekly, annualised sales could reach approximately 151,580 packs, assuming full-year availability across the network.
While illustrative rather than a forecast, this demonstrates how relatively modest consumer demand could generate meaningful volume.
The crucial test will be whether initial purchases translate into repeat orders.
International agreements could transform revenue potential
Beyond Australia, CCO is developing an ingredients supply business that could significantly broaden its revenue base.
An August distribution agreement covers Australia, New Zealand, the United States, Canada and ASEAN markets, with exclusivity conditional on approximately $25 million in purchases over three years, including $5.5 million during the first agreement year.
These thresholds are not guaranteed revenue, but their potential scale is significant relative to CCO's existing business.
A separate US beverage supply agreement also anticipates approximately $2 million in annual sales, supported by a minimum commitment of $1.582 million over two years.
Meanwhile, CCO has appointed VDriven to support expansion into US natural, organic and specialty retail.
The broader opportunity is for CCO to become both a consumer-facing kava brand and an international ingredients supplier, creating multiple channels for growth.
Can stronger sales finally deliver profitability?
The financial position remains the most important consideration.
FY26 revenue reached $8.12 million, while gross profit declined to $2.87 million, reflecting a reduction in gross margin from 42.5% to 35.3%.
Nevertheless, operating cash outflow improved 32.8% to $2.94 million, suggesting progress in controlling cash consumption.
With $669,000 in cash at June 2026 and subsequent capital raising activity, funding remains an important execution risk.
The potential upside becomes clearer under a higher-volume scenario.
At $13 million in annual revenue and a 40% gross margin, CCO could generate approximately $5.2 million in gross profit, an improvement of $2.33 million over FY26.
That would not guarantee profitability, but it could substantially improve the company's ability to cover operating expenses.
Our view: A speculative growth opportunity worth watching
We believe CCO is entering an important phase as its strategy moves from establishing distribution towards converting that access into recurring revenue.
The Australian supermarket momentum is encouraging, while FZZR and international ingredients agreements provide additional growth opportunities.
However, repeat consumer demand, margin recovery and sufficient working capital will ultimately determine whether the company can deliver sustainable earnings.
We will be watching FZZR replenishment orders, US retail commitments and actual international ingredients deliveries throughout 2027.
For speculative small-cap investors, CCO presents an interesting opportunity, but the next meaningful improvement in its investment case must come from financial performance, not simply expanding distribution.
Download The Calmer Co Initiation Report
Want to explore the investment opportunity in greater detail? The Calmer Co (ASX: CCO) Initiation Report, dated 18 October 2026, examines the company's growth strategy, supermarket expansion, international supply agreements, financial position and illustrative valuation scenarios.
Download the Full Initiation Report (PDF)
Access our comprehensive equity research to understand the opportunities, financial assumptions and key risks shaping CCO's investment outlook.